Exposure-Response Analyses of Olaparib in Real-Life Patients with Ovarian Cancer.

Mohmaed Ali, Ma Ida; Bruin, Maaike A C; Dezentjé, Vincent O; Beijnen, Jos H; Steeghs, Neeltje; Huitema, Alwin D R

Mohmaed Ali, Ma Ida; Bruin, Maaike A C; Dezentjé, Vincent O; Beijnen, Jos H; Steeghs, Neeltje; Huitema, Alwin D R.

Afiliação

Mohmaed Ali MI; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. m.mohmaed@nki.nl.
Bruin MAC; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. m.mohmaed@nki.nl.
Dezentjé VO; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Beijnen JH; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Steeghs N; Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Huitema ADR; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Pharm Res ; 40(5): 1239-1247, 2023 May.

Article em En | MEDLINE | ID: mdl-36944815

Assuntos

Neoplasias Ovarianas; Masculino; Humanos; Feminino; Neoplasias Ovarianas/tratamento farmacológico; Neoplasias Ovarianas/patologia; Ftalazinas/efeitos adversos; Piperazinas/efeitos adversos; Estimativa de Kaplan-Meier

Palavras-chave

breast cancer; exposure-response analysis; olaparib; ovarian cancer; pharmacokinetics-pharmacodynamics

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas Tipo de estudo: Observational_studies Limite: Female / Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google